Available Until 11/15/2022

Cardiology Self-Assessment Program (CardSAP) Book 1: Heart Failure (Cert # L229227)

ACPE Numbers: Various – see listing below
Pre‐sale Date: 04/20/2022
Content Release Date: 05/16/2022
Product sale end date: 11/15/2022
Activity Type: Application‐based
CE Credits: 17 contact hours (BPS and ACPE)
Activity Fee: $80 (ASHP member); $120 (non‐member)

This course is intended for board certified pharmacists in need of recertification credit and is designed based on the content outline developed by the Board of Pharmacy Specialties (BPS). The course consists of 4 learning modules (see table below) and provides up to 17 contact hours of continuing pharmacy education and/or recertification credit. 

Learners will be required to review the content and complete the associated online assessments. The learner must be able to correctly answer the questions based upon their interpretation of the content, as well as “baseline specialty-specific knowledge and/or easily retrievable information.” For purposes of this course, “baseline specialty-specific knowledge and/or easily retrievable information” is defined as product labeling and well-established standards of practice in the specialty practice. 

These activities are part of the ACCP and ASHP professional development program for BCCP recertification approved by the BPS.

The American College of Clinical Pharmacy and American Society of Health‐System Pharmacists are accredited by the Accreditation Council for Pharmacy Education as providers of continuing pharmacy education.

The target audience for Cardiology Self-Assessment Program (CardSAP) Book 1: Heart Failure is board-certified cardiology pharmacy specialists caring for patients who have developed cardiac arrhythmias and/or thromboembolic disorders.

Board certified pharmacists are eligible to receive up to 17 hours of recertification credit for completing this course. To earn recertification credit, learners must review the activity content and successfully complete the online assessments by the deadline. Only completed assessments will be eligible for credit; no partial or incomplete assessments will be processed. You are allowed only one attempt to successfully complete this assessment.

Learning Activity

ACPE Number

Contact Hours (ACPE and BPS)

Assessment Pass Point

Heart Failure I




Heart Failure II




Heart Failure III



Heart Failure IV 0217-9999-22-043-H01-P 4.5 75%

Heart Failure I
ACPE Number: 0217-9999-22-040-H01-P
Chapter: Universal Definition and Classification of Heart Failure

  • Account for how heart failure (HF) is diagnosed using signs, symptoms, and other objective markers.
  • Distinguish between existing definitions of HF related to ejection fraction and staging and the updated universal definition and classification of HF.
  • Evaluate how changes to the definition of HF will affect future clinical research and therapeutic approaches. 

Chapter: New Therapies for Chronic Heart Failure

  • Analyze literature supporting the use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) in patients with chronic heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF) for use in clinical decision-making.
  • Evaluate literature assessing the use of SGLT2i in patients at risk of developing HFrEF including chronic kidney disease, diabetes, and/or atherosclerosis for use in clinical decision-making.
  • Justify use of sacubitril/valsartan in patients with chronic heart failure with mildly reduced ejection fraction (HFmrEF) and/or chronic HFrEF with New York Heart Association (NYHA) functional class IV symptoms in the context of clinical decision-making.
  • Assess literature supporting use of vericiguat in patients with chronic HFrEF for use in clinical decision-making.
  • Develop an evidence-based pharmacotherapeutic regimen for a patient with chronic heart failure. 

Heart Failure II
ACPE Number: 0217-9999-22-041-H01-P
Chapter: Optimal Management of Chronic Heart Failure During Hospitalization

  • Design an evidence-based plan to optimize guideline-directed medical therapy and prevent the clinical sequelae of heart failure.
  • Describe appropriate indications for holding guideline-directed medical therapy during acute decompensated heart failure and the impact on clinical outcomes after hospital discharge.
  • Develop a follow-up plan to maintain and optimize pharmacologic therapy and prevent heart failure readmissions. 

Chapter: Palliative Care for Patients with Heart Failure

  • Assess the benefits of and barriers to palliative care or hospice referrals for patients with heart failure.
  • Design evidence-based pharmacotherapy regimens for patients with common symptoms in heart failure including pain, dyspnea, and/or depression.
  • Develop deprescribing recommendations for patients based on anticipated prognosis and agreed-upon goals of care.
  • Apply pharmacologic and physiologic principles to end-of-life scenarios unique to the patients with heart failure. 

Heart Failure III
ACPE Number: 0217-9999-22-042-H01-P
Chapter: Cardiac Amyloidosis

  • Distinguish the differences between light-chain (AL) amyloidosis and transthyretin-related amyloidosis (ATTR).
  • Design an appropriate workup for a patient with cardiac amyloidosis.
  • Develop an appropriate initial treatment regimen and monitoring plan for a patient with AL amyloidosis and ATTR on the basis of risk stratification.
  • Develop appropriate counseling points on therapy recommendations for AL amyloidosis and ATTR.
  • Apply best supportive care measures and monitoring for a patient with AL amyloidosis and ATTR.
  • Assess the financial impact of therapy of disease-modifying agents in ATTR. 

Chapter: Hypertrophic Cardiomyopathy

  • Evaluate patients for patterns of inheritance for hypertrophic cardiomyopathy (HCM) and implications of genotypic carrier status and phenotypic expression of disease.
  • Distinguish candidacy for HCM therapies based on presence of left ventricular outflow tract obstruction, persistence and severity of heart failure (HF) symptoms.
  • Evaluate the place in therapy of pharmacotherapeutic treatments for symptomatic HCM including β-blockers, calcium channel blockers, disopyramide, and mavacamten.
  • Justify recommendations for patients with HCM related to sudden cardiac death prevention, atrial fibrillation, exercise, and end-stage HF. 

Heart Failure IV
ACPE Number: 0217-9999-22-043-H01-P
Interactive Case: Systematic Reviews and Meta-analysis in Heart Failure

  • Differentiate systematic reviews and meta-analyses from other types of scientific reviews.
  • Assess the credibility of systematic reviews and meta-analyses in heart failure (HF).
  • Apply results from systematic reviews and meta-analyses in HF to clinical practice. 

Interactive Case: Remote Patient Monitoring in Heart Failure

  • Evaluate and monitor patients for heart failure (HF) signs and symptoms to reduce morbidity.
  • Develop a noninvasive telemonitoring strategy to implement during a remote health visit.
  • Justify the role of invasive monitoring devices and evaluate hemodynamic parameters.
  • Assess a patient’s HF medication regimen on the basis of subjective and objective evidence collected by modern telemonitoring modalities.
  • Design a remote HF visit using tools for telemonitoring.

Series Editors

Cynthia A. Jackevicius, Pharm.D., M.Sc., FCCP, FCSHP, FAHA, FCCS, FACC, BCPS-AQ Cardiology, BCCP
Professor, Pharmacy Practice
College of Pharmacy
Western University of Health Sciences
Clinical Pharmacy Specialist, Cardiology
VA Greater Los Angeles Healthcare System
Los Angeles, California 

J. Herbert Patterson, Pharm.D., FCCP, FHFSA
Professor of Pharmacy Research Professor of Medicine
Executive Vice Chair, Division of Pharmacotherapy and Experimental Therapeutics
UNC Eshelman School of Pharmacy University of North Carolina at Chapel Hill
Chapel Hill, North Carolina 

Faculty Panel Chair

Jo E. Rodgers, Pharm.D., FCCP, FAHA, FHFSA, BCPS, BCCP
Director, Postdoctoral Programs
Vice Chair of Professional Education and Practice,
Division of Pharmacotherapy and Experimental Therapeutics
UNC Eshelman School of Pharmacy
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina 


Justin Arnall, Pharm.D., BCOP
Clinical Coordinator, Hematology
Atrium Health Specialty Pharmacy Service
Atrium Health
Charlotte, North Carolina 

Theodore J. Berei, Pharm.D., MBA, BCCP
Clinical Pharmacist
Advanced Heart Failure and Transplant Cardiology
University of Wisconsin Hospitals and Clinics
Madison, Wisconsin 

Jonathan D. Cicci, Pharm.D., BCPS, BCCP, CPP
Clinical Pharmacy Specialist, Cardiology
Department of Pharmacy
University of North Carolina Medical Center
Chapel Hill, North Carolina 

Megan M. Clarke, Pharm.D., BCPS, BCCP, CPP
Clinical Pharmacy Specialist
Cardiology Coordinator, PGY2 Cardiology Pharmacy Residency
University of North Carolina Hospitals
Chapel Hill, North Carolina 

Kathleen D. Faulkenberg, Pharm.D. , FHFSA, BCPS
Clinical Coordinator, Cardiovascular Clinical Pharmacy Services
Department of Pharmacy
University of Kentucky Healthcare
Lexington, Kentucky 

Mitchell E. Hughes, Pharm.D., BCPS, BCOP
Clinical Pharmacy Specialist, Hematology/Oncology/Cellular Therapy
Lymphoma Program and Lymphoma Translational Research
Department of Pharmacy
Abramson Cancer Center at the Hospital of the Universityof Pennsylvania
Philadelphia, Pennsylvania 

Kevin T. Kissling, Pharm.D., BCPS
Specialty Practice Pharmacist
Department of Pharmacy
The Ohio State University Wexner Medical Center
Columbus, Ohio 

Robert L. Page II, Pharm.D., MSPH, FCCP, FAHA, FHFSA, FASHP, BCPS-AQ Cardiology
Departments of Clinical Pharmacy, Physical Medicine, and Medicine
University of Colorado Schools of Pharmacy and Medicine
Aurora, Colorado 

Jennifer Pruskowski, Pharm.D., BCPS, BCGP, CPE
Assistant Professor
Director of Geriatric Pharmacy Research and Education
Division of Geriatric Medicine
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania 

Diana M. Sobieraj, Pharm.D., FCCP
Director of Assessment and Associate Professor
Department of Pharmacy Practice
University of Connecticut School of Pharmacy
Storrs, Connecticut 

Joseph S. Van Tuyl, Pharm.D., BCCP
Associate Professor
Department of Pharmacy Practice
St. Louis College of Pharmacy at UHSP in St. Louis
St. Louis, Missouri 

Diana Violanti, Pharm.D., BCPS
Clinical Pharmacist Specialist, Supportive and Palliative Care
Department of Pharmacy
Roswell Park Comprehensive Cancer Center
Buffalo, New York 

Lucianne M. West, Pharm.D., BCCP
Clinical Pharmacy Specialist
Department of Pharmacy
Tufts Medical Center
Boston, Massachusetts

Snehal Bhatt, Pharm.D., BCPS
Professor of Pharmacy Practice
Department of Pharmacy Practice
Massachusetts College of Pharmacy and Health Sciences
Boston, Massachusetts 

Scott Bolesta, Pharm.D., FCCP, BCPS
Associate Professor
Department of Pharmacy Practice
Wilkes University
Wilkes-Barre, Pennsylvania 

James C. Coons, Pharm.D., FCCP, FACC, BCCP
Department of Pharmacy and Therapeutics
University of Pittsburgh School of Pharmacy
Clinical Pharmacist, Cardiology
UPMC Presbyterian Hospital
Pittsburgh, Pennsylvania 

Katherine Crawford, Pharm.D., AACC, BCCP
Clinical Pharmacist III, Cardiology
Department of Clinical Pharmacy Services
OhioHealth, Riverside Methodist Hospital
Columbus, Ohio 

Alexandra Daniels, Pharm.D., FACC, FCCP, BCCP, BCPS
Clinical Pharmacy Specialist
Advocate Medical Group (Advocate Aurora Health)
Chicago, Illinois 

Steven P. Dunn, Pharm.D., FAHA, FCCP, BCPS
Pharmacy Clinical Coordinator – Cardiology
Department of Pharmacy
University of Virginia Health System
Charlottesville, Virginia 

Samuel P. Eckel, Pharm.D., BCCP, CACP
Acute Care Clinical Pharmacist
Enterprise Pharmacy
Geisinger Medical Center
Danville, Pennsylvania 

Laura A. Fuller, Pharm.D., BCPS, BCCP
Clinical Pharmacy Specialist
Department of Pharmacy Services
Baptist Memorial Hospital - DeSoto
Southaven, Mississippi 

Wendy M. Gabriel, Pharm.D., BCPS, BCCP
Associate Professor
Department of Pharmacy Practice
South College School of Pharmacy
Knoxville, Tennessee 

Michael A. Gillette, Pharm.D., FHFSA, AACC, BCPS, BCCP
Clinical Pharmacy Specialist, Cardiology
Michael DeBakey VA Medical Center
Houston, Texas 

Jaclynne R. Gowen, Pharm.D., BCCP
Clinical Ambulatory Pharmacist - Cardiology
Department of Pharmacy
Wentworth-Douglass Hospital
Dover, New Hampshire 

Michelle J. Lew, Pharm.D., BCPS, BCCP
Clinical Pharmacist
Department of Pharmacy
Scripps Memorial Hospital, La Jolla
San Diego, California 

Tracy E. Macaulay, Pharm.D., FCCP, FACC, BCPS-AQ, Cardiology, BCCP
Associate Clinical Professor
Department of Pharmacy Practice and Science
University of Kentucky College of Pharmacy
Lexington, Kentucky 

Kelsey Mews, Pharm.D., BCACP, BCCP
Ambulatory Care Clinical Pharmacist
Department of Pharmacy
Mayo Clinic Health System
Mankato, Minnesota 

Evan J. Peterson, Pharm.D., BCCP
Clinical Pharmacy Specialist - Cardiology
Department of Pharmacy
Ascension Seton Medical Center
Austin, Texas 

Kerry K. Pickworth, Pharm.D., FCCP, BCPS-AQ Cardiology
Clinical Pharmacy Specialist - Cardiology
Richard M. Ross Heart Hospital
The Ohio State University Wexner Medical Center
Columbus, Ohio 

Kelly C. Rogers, Pharm.D., FCCP, FACC, BCCP
Professor of Clinical Pharmacy and Translational Science
Department of Clinical Pharmacy and Translational Science
University of Tennessee Health Science Center College of Pharmacy
Cardiology Clinical Specialist
Department of Pharmacy
Memphis, Tennessee 

Thomas W. Szymanski, Pharm.D., BCCP
Clinical Pharmacy Specialist – Cardiovascular Critical Care
West Virginia University Medicine
Morgantown, West Virginia 

Elizabeth Tien, Pharm.D., BCPS, BCCP
Clinical Pharmacist Specialist, Cardiology/General Medicine
Department of Pharmaceutical Services
UCSF Medical Center
San Francisco, California 

Benjamin W. Van Tassell, Pharm.D., FCCP, BCPS
Vice Chair for Research
Department of Pharmacotherapy and Outcomes Science
Virginia Commonwealth University School of Pharmacy
Richmond, Virginia 

Kathryn Weber, Pharm.D., BCPS, BCCP
Clinical Pharmacy Specialist, Cardiology
Department of Pharmacy
The Christ Hospital Health Network
Cincinnati, Ohio 


The authors gratefully acknowledge Prashanth S. Iyer, Pharm.D., BCPS for his contributions to the development and creation of this chapter.

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support and the Accreditation Council for Pharmacy Education’s Standards for Commercial Support, the American Society of Health-System Pharmacists (ASHP) and the American College of Clinical Pharmacy (ACCP) require that all individuals involved in the development of activity content disclose their relevant financial relationships. A person has a relevant financial relationship if the individual of his or her spouse/partner has a financial relationship (e.g. employee, consultant, research grant recipient, speakers bureau, or stockholder) in any amount occurring the in the last 12 months with a commercial interest whose products or series may be discussed in the educational activity content over which the individual has control. The existence of these relationships is provided for the information of participants and should not be assumed to have an adverse impact on the content. 

All faculty and planners for ACCP and ASHP education activities are qualified and selected by ACCP and ASHP and required to disclose any relevant financial relationships with commercial interests. ACCP and ASHP identifies and resolves conflicts of interest prior to an individual’s participation in development of content for an educational activity. Anyone who refuses to disclose relevant financial relationships must be disqualified from any involvement with a continuing pharmacy education activity.

No one in control of the content of this activity has a relevant financial relationship (RFR) with an ineligible company. 

  • Consultancies: Justin Arnall (CTI BioPharma); James C. Coons (Bristol-Myers Squibb; Alnylam Pharmaceuticals); Steve Dunn (Abiomed); Mitchell Hughes (AstraZeneca; Genzyme; Janssen; AbbVie; Karyopharm); Kevin T. Kissling (Nuwellis); Kerry K. Pickworth (ASHP); Lucianne M. West (Astra Zeneca); Cynthia Jackevicius (AHA, CSHP); Herb Patterson (Novartis, Alnylam Advisory Board, SQ Innovation)

  • Stock Ownership: Snehal Bhatt (Sarepta Therapeutics)

  • Grants: Scott Bolesta (Wilkes University); James C. Coons (United Therapeutics); Kathleen D. Faulkenburg (NIH); Mitchell Hughes (HOPA and Acerta Pharma); Ben Van Tassell (NIH National Heart, Lung, and Blood Institute; NIH National Institute on Aging; Serpin Pharma); Diana Stewart Violanti (Medstar Health Research Institute); Cynthia Jackevicius (Heart and Stroke Foundation of Canada)

  • Honoraria: Snehal Bhatt (Janssen Pharmaceuticals); Justin Arnall (Novo Nordisk); Mitchell Hughes (ACCP; ASHP)

  • Other: Mitchell Hughes (National Comprehensive Cancer Network Chemotherapy Order Templates consultant; Oncolink consultant 

All other planners, presenters, reviewers, ACCP and ASHP staff and others with an opportunity to control content report no financial relationships relevant to this activity. 

Activities consist of educational materials, assessments, and activity evaluations. In order to receive continuing pharmacy education credit, learners must:

  • Complete the attestation statement
  • Review all content
  • Complete and pass the assessments
  • Complete the evaluations 

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity. 

These activities were developed by ACCP and ASHP.